Yuting Wang

Fuzuloparib with or without apatinib in patiënten met HER2-negative metastatic breast cancer with germline BRCA1/2 mu...

Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metas...